Group 1 - The company announced the establishment of a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., with an investment of 70 million yuan to support its strategic planning and R&D needs [1][3] - The company operates in various fields including oncology, microbiology, cardiovascular, detoxification, digestive system, musculoskeletal system, gynecology, and neurology [1] - The R&D process is managed by the headquarters, with production bases conducting projects based on their characteristics and market layout, including both innovative and generic drug development [1] Group 2 - The company received a notice of acceptance for the market application of Amber Dihydroaminoacridine Tablets, a new drug for treating mild to moderate Alzheimer's disease, which has undergone extensive clinical trials since 2007 [2] - The company emphasizes that new drug development is a long-term, high-investment, and high-tech process, with uncertainties regarding market prospects and economic returns [2] - The establishment of the subsidiary is part of the company's strategy to transform into an innovation-driven modern pharmaceutical enterprise, enhancing its core competitiveness and ensuring sustainable development [3]

Core Viewpoint - Tonghua Golden Horse plans to invest 70 million yuan to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd, to enhance its strategic focus on innovation-driven development in the pharmaceutical industry [1] Group 1: Investment and Strategic Development - The investment of 70 million yuan will be sourced from the company's own or raised funds [1] - The establishment of the subsidiary aligns with the company's strategy to transform into an innovation-driven modern pharmaceutical enterprise [1] - The move aims to strengthen the company's capabilities in mergers and acquisitions within the innovative drug sector, thereby enhancing its core competitiveness [1] Group 2: Long-term Sustainability - The initiative is intended to inject new momentum into the company's long-term sustainable development [1]

Core Viewpoint - Tonghua Jinma (000766) announced the establishment of a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., with an investment of 70 million yuan to support its strategic shift towards becoming an innovation-driven modern pharmaceutical enterprise [1] Group 1 - The investment of 70 million yuan will be funded through the company's own or raised funds [1] - The establishment of the subsidiary is part of the company's strategy to enhance its mergers and acquisitions and layout in the innovative drug industry [1] - This move aligns with the company's overall strategic planning and research and development needs [1]

Core Viewpoint - Tonghua Golden Horse (000766.SZ) plans to invest 70 million yuan to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd, to support its strategic shift towards becoming an innovation-driven modern pharmaceutical enterprise [1] Group 1: Investment and Strategic Development - The investment of 70 million yuan will be sourced from the company's own or raised funds [1] - The establishment of the subsidiary is aimed at enhancing the company's capabilities in mergers and acquisitions within the innovative pharmaceutical industry [1] - This move is part of the company's long-term strategy to boost its core competitiveness and ensure sustainable development [1]

Core Viewpoint - Tonghua Golden Horse (000766.SZ) plans to invest 70 million yuan to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd, to support its strategic shift towards becoming an innovation-driven modern pharmaceutical enterprise [1] Group 1: Investment and Strategic Development - The investment of 70 million yuan will be sourced from the company's own funds or raised funds [1] - The establishment of the subsidiary is aligned with the company's strategy to enhance its capabilities in the innovative drug industry through mergers and acquisitions [1] - This move aims to strengthen the company's core competitiveness and inject new momentum into its long-term sustainable development [1]

Group 1 - The company, Tonghua Golden Horse, plans to invest RMB 70 million to establish a wholly-owned subsidiary named Guilin Jinma Innovation Investment Co., Ltd. [1] - The investment is aligned with the company's overall strategic planning and research and development needs [1] - The name of the subsidiary is provisional and will be confirmed by the relevant administrative authorities [1]

证券代码：000766 证券简称：通化金马 公告编号：2025-39 一、对外投资概述 通化金马药业集团股份有限公司（以下简称 "公司"）于 2025 年 11 月 6 日召开第十一届董事会 2025 年第八次临时会议，审议通过了《关于对外投资设 立全资子公司的议案》。根据公司整体战略规划和研发业务需要，公司拟使用自 有或自筹资金人民币 7,000 万元投资设立全资子公司桂林金马创新投资有限公 司（暂定名，以工商行政管理部门核准名称为准）。 根据《深圳证券交易所股票上市规则》和《通化金马药业集团股份有限公司 章程》等有关规定，本次投资设立子公司事项在公司董事会审批权限范围内，无 需提交公司股东会审议。 本次投资设立子公司事项不构成关联交易，亦不构成《上市公司重大资产重 组管理办法》规定的重大资产重组。 二、投资标的的基本情况 （一）公司名称：桂林金马创新投资有限公司 通化金马药业集团股份有限公司 关于对外投资设立全资子公司的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 （二）公司类型：有限责任公司 （三）注册资本：7,000 万元人民币 （四）法定代表 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-38 通化金马药业集团股份有限公司 第十一届董事会 2025 年第八次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会2025年第八次临时会议通知 于2025年11月5日以微信和电子邮件形式送达全体董事。 2.2025 年 11 月 6 日上午 9 时 30 分以现场和通讯方式召开。 3.会议应到董事9人，实到董事9人。 4.会议由董事长张玉富先生主持，部分高管人员列席了本次会议。 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定。 二、董事会会议审议情况 审议并通过关于对外投资设立全资子公司的议案 根据公司整体战略规划和研发业务需要，公司拟使用自有或自筹资金人民币 7,000 万元投资设立全资子公司桂林金马创新投资有限公司（暂定名，以工商行政 管理部门核准名称为准）。有关内容详见公司同日刊登于巨潮资讯网上的《关于对外 投资设立全资子公司的公告》。 表决结果：同意 9 票， ...

Core Viewpoint - The company plans to invest CNY 70 million to establish a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., to enhance its capabilities in the innovative pharmaceutical sector and align with its strategic transformation towards a modern, innovation-driven pharmaceutical enterprise [1] Investment Details - The investment amount is CNY 70 million, which will be sourced from the company's own or raised funds [1] - The registered capital of the new subsidiary will also be CNY 70 million [1] - The location of the new subsidiary is in Guilin City, specifically in the Lingui District [1] Strategic Intent - The investment aims to strengthen mergers and acquisitions in the innovative drug industry and optimize the company's industrial layout [1] - This move is in line with the company's strategic planning to transition into an innovation-driven modern pharmaceutical enterprise [1] Approval and Compliance - The investment has undergone the necessary board approval process and does not require shareholder meeting review [1] - The transaction does not constitute a related party transaction or a major asset restructuring [1] Future Considerations - The newly established company has not yet completed its business registration, indicating that future revenue remains uncertain [1] - The company plans to enhance its management mechanisms to mitigate risks associated with this investment [1]

Core Viewpoint - Tonghua Golden Horse announced the establishment of a wholly-owned subsidiary, Guilin Jinma Innovation Investment Co., Ltd., with an investment of 70 million yuan to enhance its strategic transformation in the innovative pharmaceutical industry [1] Group 1: Company Actions - The company will hold its 11th board meeting on November 6, 2025, to approve the investment proposal [1] - The investment will be funded through the company's own or raised funds, and the company will hold 100% of the new subsidiary [1] - The investment decision falls within the board's approval authority and does not constitute a related party transaction or a major asset restructuring [1] Group 2: Strategic Intent - The purpose of this investment is to conduct mergers and acquisitions in the innovative pharmaceutical sector as part of the company's transformation strategy [1] - The company acknowledges that the investment may be influenced by industry policies but believes it will help optimize its industrial layout [1]